Extending patient survival with next-generation treatment combinations.
Development Pipeline
We are advancing a pipeline of innovative immuno-oncology programs.
Coherus is developing a diversified pipeline of immuno-oncology therapeutics that can be part of next-generation treatment combinations to extend survival for patients with cancer across difficult-to-treat tumor types. Our pipeline programs have distinct targets designed to inhibit immune suppressive mechanisms in the tumor microenvironment with the goal of delivering powerful anti-tumor activity and, ultimately, transforming outcomes for patients. Our pipeline includes a range of novel preclinical and clinical-stage immuno-oncology programs currently in development.
Coherus-led Immuno-oncology Programs
Program
Description
Indication
Stage
- Preclinical
- Phase 1
- Phase 2
- Pivotal
- Approved
Anti-PD-1 monoclonal antibody
Nasopharyngeal Carcinoma
(IL combo with chemo)
(IL combo with chemo)
Approved
Nasopharyngeal Carcinoma
(2L/3L monotherapy)
(2L/3L monotherapy)
Approved
Approved
Approved
IL-27 antagonist monoclonal antibody
Hepatocellular Carcinoma
Phase 2
Non-Small Cell Lung Cancer
Phase 2
Phase 2
Phase 2
* Coherus owns the rights to LOQTORZI® in the United States and Canada.
Licensed Immuno-oncology Programs
Program
Description
Indication
Stage
- Preclinical
- Phase 1
- Phase 2
- Pivotal
- Approved
GSK4381562^
Anti-PVRIG monoclonal antibody
Solid Tumors
Phase 1
Phase 1
^ Coherus has licensed worldwide rights to GSK.
Learn more about toripalimab, our next generation anti-PD-1 monoclonal antibody.
